Literature DB >> 26142452

Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial.

Ruanne V Barnabas1, Jared M Baeten2, Jairam R Lingappa3, Katherine K Thomas4, James P Hughes5, Nelly R Mugo4, Sinead Delany-Moretlwe6, Glenda Gray7, Helen Rees6, Andrew Mujugira8, Allan Ronald9, Wendy Stevens10, Saidi Kapiga11, Anna Wald12, Connie Celum2.   

Abstract

Human immunodeficiency virus (HIV)-infected persons have higher rates of herpes zoster than HIV-uninfected individuals. We assessed whether twice daily treatment with 400 mg of oral acyclovir reduces the incidence of herpes zoster in a randomized, double-blind, placebo-controlled trial among 3408 persons coinfected with HIV and herpes simplex virus type 2. During 5175 person-years of follow-up, 26 cases of herpes zoster occurred among those assigned acyclovir, compared with 69 cases among those assigned placebo (rates, 1.00 and 2.68/100 person-years, respectively), a relative decrease of 62% (hazard ratio, 0.38; 95% confidence interval, .24-.67; P < .001). Daily acyclovir prophylaxis significantly reduced herpes zoster incidence among HIV-infected persons.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  HIV; VZV; acyclovir; acyclovir prophylaxis; herpes zoster; shingles

Mesh：

Substances：

Year:  2015        PMID： 26142452      PMCID： PMC4721901          DOI： 10.1093/infdis/jiv318

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Clinical practice. Herpes zoster.

Authors:  John W Gnann; Richard J Whitley
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

2.  Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa.

Authors:  Kate Shearer; Mhairi Maskew; Toyin Ajayi; Rebecca Berhanu; Pappie Majuba; Ian Sanne; Matthew P Fox
Journal:  Int J Infect Dis       Date:  2014-03-25       Impact factor: 3.623

3.  The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era.

Authors:  Kelly A Gebo; Rita Kalyani; Richard D Moore; Michael J Polydefkis
Journal:  J Acquir Immune Defic Syndr       Date:  2005-10-01       Impact factor: 3.731

4.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Authors:  Jairam R Lingappa; Jared M Baeten; Anna Wald; James P Hughes; Katherine K Thomas; Andrew Mujugira; Nelly Mugo; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; James Kiarie; Carey Farquhar; Grace John Stewart; Joseph Makhema; Myron Essex; Edwin Were; Kenneth H Fife; Guy de Bruyn; Glenda E Gray; James A McIntyre; Rachel Manongi; Saidi Kapiga; David Coetzee; Susan Allen; Mubiana Inambao; Kayitesi Kayitenkore; Etienne Karita; William Kanweka; Sinead Delany; Helen Rees; Bellington Vwalika; Amalia S Magaret; Richard S Wang; Lara Kidoguchi; Linda Barnes; Renee Ridzon; Lawrence Corey; Connie Celum
Journal:  Lancet       Date:  2010-02-12       Impact factor: 79.321

5.  Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.

Authors:  Sophie Grabar; Pierre Tattevin; Hana Selinger-Leneman; Arnaud de La Blanchardiere; Pierre de Truchis; Christian Rabaud; David Rey; Vincent Daneluzzi; Samuel Ferret; Anne-Sophie Lascaux; Thomas Hanslik; Dominique Costagliola; Odile Launay
Journal:  Clin Infect Dis       Date:  2015-01-18       Impact factor: 9.079

6.  Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells.

Authors:  Ofer Levy; Jordan S Orange; Patricia Hibberd; Sharon Steinberg; Phillip LaRussa; Adriana Weinberg; S Brian Wilson; Angela Shaulov; Gary Fleisher; Raif S Geha; Francisco A Bonilla; Mark Exley
Journal:  J Infect Dis       Date:  2003-09-26       Impact factor: 5.226

7.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Authors:  C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 8.  Executive Summary: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations From the National Institutes of Health, the Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman
Journal:  J Pediatric Infect Dis Soc       Date:  2013-11-27       Impact factor: 3.164

9.  Herpes zoster and human immunodeficiency virus infection.

Authors:  S P Buchbinder; M H Katz; N A Hessol; J Y Liu; P M O'Malley; R Underwood; S D Holmberg
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

10.  Varicella zoster virus in solid organ transplantation.

Authors:  S A Pergam; A P Limaye
Journal:  Am J Transplant       Date:  2013-03       Impact factor: 8.086
View more
  6 in total

1.  T Cell Immunity to Varicella-Zoster Virus in the Setting of Advanced HIV and Multiple Varicella-Zoster Virus Recurrences.

Authors:  Rachel A Bender Ignacio; Meena S Ramchandani; Kerry J Laing; Christine M Johnston; David M Koelle
Journal:  Viral Immunol       Date:  2016-11-21       Impact factor: 2.257

2.  Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals.

Authors:  Kenneth H Fife; Kenneth Mugwanya; Katherine K Thomas; Jared M Baeten; Connie Celum; Elizabeth Bukusi; Guy de Bruyn; Andrew Mujugira; Bellington Vwalika; Anna Wald; Jairam R Lingappa
Journal:  J Infect Dis       Date:  2015-12-23       Impact factor: 5.226

Review 3.  Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression.

Authors:  Arshi Munawwar; Sarman Singh
Journal:  J Lab Physicians       Date:  2016 Jan-Jun

Review 4.  Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.

Authors:  Nancy F Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2017-08-05

5.  Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy.

Authors:  Nathaniel B Erdmann; Heather A Prentice; Anju Bansal; Howard W Wiener; Greer Burkholder; Sadeep Shrestha; Jianming Tang
Journal:  Front Public Health       Date:  2018-03-12

6.  A rare case of herpes zoster ophthalmicus after photodynamic therapy.

Authors:  Madison Bradley; Sonal Muzumdar; Neda Shahriari; Marti J Rothe; Madina Falcone
Journal:  Int J Womens Dermatol       Date:  2020-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.